Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Phase-Based Progress Estimates
Effectiveness
Safety
Prostate Cancer+1 More
Stereotactic Body Radiation Therapy (SBRT) - RadiationEligibility
18+
Male
What conditions do you have?
Select
Eligibility
18+
Male
What conditions do you have?
Select
Study Summary
This trial is testing whether a treatment called SBRT is effective for treating prostate cancer in patients who have an unfavorable intermediate-risk. The researchers will also look at whether the Decipher test can help predict which patients will benefit from more extensive radiation treatment.
Eligible Conditions
- Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Other trials for Prostate Cancer
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 2 years
2 years
Rate of biochemical progression free survival
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Prostate Cancer
Side Effects for
Gem + Xeloda + SBRT
21%Anemia
18%Neutropenia
15%Hypoalbuminemia
15%White blood cell decreased ( leukopenia)
15%Diarrhea
12%Liver Dysfunction
9%Hand-Foot
3%Bleeding
3%Stroke
3%Abdominal Infection
3%Ileus
3%Mucositis
3%Edema
3%Dermatitis
3%Platelet count decreased ( Thrombocytopenia)
Trial Design
2 Treatment Groups
Patients with high risk Decipher scores
1 of 2
Patients with low-intermediate risk Decipher scores
1 of 2
Experimental Treatment
145 Total Participants · 2 Treatment Groups
Primary Treatment: Stereotactic Body Radiation Therapy (SBRT) · No Placebo Group · Phase 2
Patients with high risk Decipher scores
Radiation
Experimental Group · 1 Intervention: Stereotactic Body Radiation Therapy (SBRT) · Intervention Types: RadiationPatients with low-intermediate risk Decipher scores
Radiation
Experimental Group · 1 Intervention: Stereotactic Body Radiation Therapy (SBRT) · Intervention Types: RadiationTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Body Radiation Therapy (SBRT)
2014
Completed Phase 2
~630
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,202 Total Patients Enrolled
127 Trials studying Prostate Cancer
65,281 Patients Enrolled for Prostate Cancer
Michael Zelefsky, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
11 Previous Clinical Trials
827 Total Patients Enrolled
8 Trials studying Prostate Cancer
520 Patients Enrolled for Prostate Cancer
Eligibility Criteria
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have Grade Group 2 or 3.
You have a T2b-T2c lesion.
You have a PSA level of 10 to 20 ng/mL.
You have a pathologically proven diagnosis of prostate adenocarcinoma within 12 months of enrollment.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments